That oestrogen replacement for osteoporosis prevention should no longer be a bone of contention T G Palferman Virginia Woolf was contemptuous of much that was written about women by men' and believed their motives were based largely on anger. The hypothesis now proposed, that effective treatment to protect women from the misery of osteoporosis should be more actively promoted, would perhaps have made some amends and met with approbation from the lady of Bloomsbury.
More than half a century since Fuller Albright observed a relation between osteoporosis and oestrogen deficiency2 only a minority of postmenopausal women today receive oestrogen replacement therapy.3 Popularity among potential recipients and their doctors has waxed and waned as difficulties in evaluating risks and benefits have sown the seeds of confusion and controversy. There is now substantial evidence in favour of beneficial effects on many counts and for protection against osteoporosis, in particular. (For the purpose of this article oestrogen replacement therapy whether taken alone or in combination with progestogens is synonymous with hormone replacement therapy-HRT.)
Bone mineral content and bone mineral density (BMD) begin to decline in early mid-life along with natural aging in other systems. During the first decade of the menopause an accelerated phase of bone loss is superimposed on the involutional reduction in BMD. There are now ample data to demonstrate that BMD falls in proportion to declining oestrogen levels with resultant increase in fracture risk.f8 Conversely, oestrogen replacement preserves bone mass and reduces fracture risk"'6 with its protective effect greater the earlier HRT is introduced. 7 The results of four international conferences on probably influences calcitonin levels and vitamin D3 activity. Those oestrogens used in HRT preparations are so-called 'natural' hormones as they are identical to endogenous oestrogens in their action. Of these, oestradiol and oestrone are manufactured, whereas the naturally occurring conjugated equine oestradiols are extracted from the urine of pregnant mares. These are in contrast with the synthetic oestrogens, such as ethinyl oestradiol, used in the oral contraceptive pill, which have a biological activity of between 80 and 200 times greater than that of the natural hormone. More efficient suppression of follicle stimulating hormone thereby ensuring contraceptive effectiveness. An appreciation of these differences is necessary in order to understand the separate side effect profiles. Progestogens: advantages and disadvantages For the 80% of postmenopausal women with an intact uterus the addition of progestogen is the rule in order to protect against endometrial carcinoma. It is reasonable, therefore, to consider what, if any, effect progestogens themselves have on breast tissue, bones, heart, and blood vessels and any modulatingoropposing effects they might have against oestrogen activity on those target organs.
Combination therapies currently use the progestogens norethisterone and norgestrel, and it is the 12 day progestogen phase of HRT which can cause equivalent symptoms to true premenstrual syndrome. For some women it is the occasional irregular bleeding, or the continuation or return of menstruation which proves undesirable. All too often combination HRT is abandoned too swiftly owing to troublesome side effects. Just as with oestrogens where one preparation is not universally acceptable, so changing the 'brand' of HRT and therefore the types of progestogen can be helpful. For others tailor-made regimens will be needed by combining an oestrogen with other progestogens, usually didrogesterone or medroxyprogesterone acetate, when the two tablets are prescribed separately and will not be available in a convenient calendar pack.
Progestogens being structurally similar to testosterone might be expected to counteract the cardioprotective effect of oestrogens and studies have shown this to be so. 77 Developments over the next decade are likely to result in the production of newer, better tolerated preparations with the ability both to prevent monthly bleeds yet maintain endometrial protection. The recently introduced drug tibolone (Livial), possessing weak oestrogenic, progestogenic, and androgenic properties, possibly represents the first step in that direction, although the effect on BMD of this particular combination is considered to be relatively slight.93 Nonetheless, the lack of continuing menstruation is likely to make tibolone attractive to women and might influence their choice of HRT, which will not necessarily be as advantageous to bone metabolism as the more traditional combinations. To overcome this, suggestions that all women would be better having a hysterectomy at the menopause in order to take long term unopposed oestrogens smacks of 'Brave New World' and raises yet further ethical dilemmas for the poor gynaecologist. The technique of per vaginal endometrial resection might offer a compromise but, again, the question of surgery on the grounds of convenience alone, albeit with long term gains in mind, raises interesting moral, medical, and legal questions.
In the meantime, if progestogens are to continue, there is no choice but to persevere with those presently available. It should not be forgotten that women with a uterus who use patch or implant oestrogens must still take progestogen for 12 days each month, and knowledge of compliance with these regimens is incomplete.
Who should receive oestrogen replacement? The means to diagnose osteoporosis and monitor response to treatment are now available thanks to the advent of bone densitometry. Dual energy x ray absorptiometry (DEXA) with a precision of less than 1% is currently the cheapest, safest, and most easily available technique to measure BMD and has revolutionised the investigation of osteoporosis. An additional benefit of DEXA will be to permit validation of existing treatments as well as to assess new therapeutic regimens. This A recent bulletin on osteoporosis screening issued to managers by a group commissioned by the Department of Health does not have the benefit of the information which will be forthcoming from the two large studies mentioned above. Unfortunately, the opinion of this group from the Leeds University Public Health School is open to misinterpretation. The danger being that the worth of BMD measurements in clinical practice as a whole will be questioned, thereby thwarting the -responsible attempts by clinicians to secure bone densitometry for diagnostic use in patients with an increasingly common disease. After all, the success of HRT (and whatever other measures are ultimately agreed to be appropriate for the treatment or prevention of osteoporosis) can only be determined by measuring changes in BMD.
Yet, even if widespread screening becomes the accepted wisdom some degree of selectivity will be necessary on financial grounds, and with current manpower constraints the meeting of any significant increased demand seems unlikely. Until the dilemma about screening is resolved and in view of the limited DEXA facilities in the United Kingdom a compromise is necessary. It does seem sensible that all attempts should be made by general practitioners and relevant specialists to recognise on well established clinical grounds, crude as they might be,'10407 those most vulnerable to osteoporosis. Bone mineral density should be measured whenever possible, which might require women to travel to a centre where DEXA is available. Personal experience suggests that this is acceptable as perimenopausal women tend to be a highly motivated group and any repeat measurements are unlikely to be required at intervals of less than one year.
So far, the hypothesis has centred on the aim of providing HRT to preserve bone mass. Yet osteoporosis cannot be considered in isolation, for the benefits of oestrogen replacement must be viewed in a wider context. Promoting HRT On all the evidence available the conclusion must be that promotion of HRT makes good sense on public health grounds. The financial costs/benefits are unproved, despite attempts which have been made in both the USA and the United Kingdom. "' 112 Ifthemedical profession as a whole can be persuaded by the evidence in favour of HRT it is debatable whether knowledge of the economics should influence a doctor's decision to provide the best treatment for as many patients as possible. Any restriction to the provision of a high quality clinical service for osteoporosis on financial grounds will need to be made by politicians through the managers who administer the funds. Hansard of 17 October 1991 documents a reply by Mr MacGregor, leader of the House of Commons, to a question by the member of parliament for Bradford West about changes for osteoporosis screening, in which he states, 'The service is free to NHS patients . . . What is more, there is no waiting time for that service'-so we live in hope.
Epilogue A knowledge of bone metabolism in osteoporosis on biological, cellular, and clinical levels provides intellectual opportunities to study a fascinating condition which threatens epidemic proportions. If this challenge is neglected it will fall to other disciplines to respond, with the rheumatologist left to tackle only the symptomatic relief and rehabilitation of those following crush fracture of the vertebrae and chronic disability from hip fracture-daunting and depressing prospects, important though they are.
The informed rheumatologist armed with densitometer, clinical acumen, and a few basic laboratory investigations is best placed to comprehend, investigate, and deal with those many aspects which influence osteoporosis and, in particular, to encourage HRT and monitor its beneficial effect. When the incidence offractures substantially and perceptibly reduces then, and only then, will it be possible for rheumatologists to enjoy any sense of achievement in their struggle against the looming threat of osteoporosis.
Who knows, maybe then even Germaine Greer will be impressed. 
